Last week, a major study on the risks of ductal carcinoma in situ (DCIS) was published in JAMA Oncology. The results spurred the New York Times editorial section to run not one, but four different commentaries on the results.
There were a number of interesting findings in the JAMA Oncology study, but the headline was that DCIS has potential for distant metastatic spread and can be lethal without the presence of an invasive breast cancer. Researchers also found that radiotherapy or mastectomy treatments to limit recurrence didn’t reduce breast-cancer specific mortality.
Four columnists took to the pages of the Times to reflect on the implications of the findings, including officials with the American Cancer Society and National Women’s Health Network, a University of Pennsylvania professor and a breast cancer patient who’s nearly completed treatment. Their thoughts on treatment for early cancer, patient anxiety and more can be found at the link below: